AB-205 for Lymphoma (E-CELERATE Trial)

Recruiting in Palo Alto (17 mi)

+32 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Angiocrine Bioscience

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new treatment called AB-205 to see if it can reduce severe side effects in lymphoma patients who are receiving high-dose chemotherapy and blood stem cell transplants. These patients often suffer from serious complications due to the chemotherapy. AB-205 might help protect their healthy tissues and reduce these risks.

Eligibility Criteria

Adults over 40 with Hodgkin or non-Hodgkin lymphoma, in partial or complete remission, can join this trial. They must be fit enough for high-dose chemotherapy and stem cell transplant, have good heart and lung function, normal liver enzymes, a creatinine clearance of at least 30 ml/min, and not exceed a certain weight limit. Participants must agree to use two forms of contraception if they are sexually active.

Participant Groups

The study tests whether AB-205 can prevent or lessen severe complications from high-dose chemotherapy in lymphoma patients undergoing stem cell transplants compared to a placebo. All participants will receive standard care alongside the test drug or placebo.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: AB-205 plus standard-of-care preventive and supportive therapies.Experimental Treatment1 Intervention

Group II: Placebo plus standard-of-care preventive and supportive therapies.Placebo Group1 Intervention